| MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2. | colorectal, |
| LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. | prostate, |
| It has been demonstrated that FAK depletion reduces hepatocellular carcinoma cell growth by affecting cancer-promoting genes including the pro-oncogene EZH2. | liver, |
| in vitro restoration of PAR5 expression inhibited human glioma cell proliferation, invasion and migration by binding to EZH2 and regulating oncogene expression. This finding may provide a therapeutic approach for the future treatment of glioma | glioma, |
| These findings demonstrate that PKA-mediated T372 phosphorylation reduces oncogenic EZH2 activity and reveal a novel role for the evolutionarily conserved T372 motif of EZH2 in regulating EZH2 in epithelial ovarian cancer and possibly other cancers. | ovarian, |
| Results demonstrate that EZH2 inhibition enhances HCC eradication by NK cells and that EZH2 functions, in part, as an oncogene by inhibiting immune response. | liver, |
| Results show the AcK27-HOXB9 level decreased in colon cancer patients and predicted better outcome. HOXB9 upregulated oncogenic EZH2 expression, whereas AcK27-HOXB9 suppressed it by translocating HOXB9 from nuclei into cytoplasm. AcK27-HOXB9 inhibits while non-acetylated HOXB9 promotes EZH2 expression and colon cancer progression. Thus, AcK27-HOXB9 underlies the tumor suppressive role of HOXB9. | colorectal, |
| EZH2, a target of miR-144, serves as an oncogene in LUAD. EZH2 was upregulated in lung adenocarcinoma (LUAD) cells. Its knockdown could suppress the propagation and invasion of LUAD cells. | lung, |
| data demonstrated that in brain glioma cells, the decrease of EZH2 level could suppress cell proliferation and tumorigenesis potency, and meanwhile inhibit the expressions of oncogenes including c-myc and Akt. | brain,glioma, |
| results imply that Akt regulates the methylation activity, through phosphorylation of EZH2, which may contribute to oncogenesis | None |
| The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. | None |
| Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. | None |
| p53-paralog DNp73 oncogene is repressed by IFNalpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. | None |
| KLF2 repression has an important role in EZH2 oncogenesis | None |
| Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. | None |
| Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. | None |
| FEZF2 acted as a histone deacetylase-associated repressor downregulating multiple oncogenes including EZH2 and MDM2, through direct binding to their promoters. | None |
| Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. | None |
| TET1 suppresses cancer formation by coupling DNA demethylation with DNA-PK activation of p53 and suppression of oncogenic protein EZH2. | None |
| SPRY4-IT1 repression has an important role in EZH2 oncogenesis. | None |